

Jennifer G Robinson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4517658/jennifer-g-robinson-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

286
papers

25,626
citations

64
h-index

157
g-index

321
ext. papers

30,163
ext. citations

7.4
avg, IF

6.76
L-index

#	Paper	IF	Citations
286	Effectiveness of a Novel EB Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2022 , 5, e2141898	10.4	2
285	Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.. <i>Journal of Biomedical Informatics</i> , 2022 , 104029	10.2	
284	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012). <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	
283	n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies. <i>Diabetes Care</i> , 2021 , 44, 1133-1142	14.6	12
282	Effects of menopausal hormone therapy on erythrocyte n-3 and n-6 PUFA concentrations in the Women's Health Initiative randomized trial. <i>American Journal of Clinical Nutrition</i> , 2021 , 113, 1700-1706	7	2
281	Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. <i>Nature Communications</i> , 2021 , 12, 2329	17.4	33
280	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. <i>Menopause</i> , 2021 , 28, 610-618	2.5	5
279	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. <i>Clinical Cardiology</i> , 2021 , 44, 863-870	3.3	1
278	Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts. <i>Journal of the American Heart Association</i> , 2021 , 10, e019589	6	1
277	Risk Patterns and Mortality in Postmenopausal Women Using Latent Class Analysis. <i>American Journal of Preventive Medicine</i> , 2021 , 61, e225-e233	6.1	0
276	Association of Body Mass Index With Colorectal Cancer Risk by Genome-Wide Variants. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 38-47	9.7	6
275	The neuropsychology of statin intolerance. <i>Nature Reviews Cardiology</i> , 2021 , 18, 153-154	14.8	1
274	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006548	5.8	2
273	Reticular Pseudodrusen Characteristics and Associations in the Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2), an Ancillary Study of the Women's Health Initiative. <i>Ophthalmology Retina</i> , 2021 , 5, 721-729	3.8	5
272	Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. <i>PLoS Medicine</i> , 2020 , 17, e1003102	11.6	17
271	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , 2020 , 9, 447-465	2.8	3
270	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. <i>American Heart Journal</i> , 2020 , 225, 88-96	4.9	3

269	Early pregnancy prediction of gestational diabetes mellitus risk using prenatal screening biomarkers in nulliparous women. <i>Diabetes Research and Clinical Practice</i> , 2020 , 163, 108139	7.4	5
268	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <i>PLoS ONE</i> , 2020 , 15, e0240166	3.7	1
267	A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients. <i>AMIA Summits on Translational Science Proceedings</i> , 2020 , 2020, 664-673	1.1	1
266	Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 707-719	4.9	0
265	Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group. <i>Journal of the American Heart Association</i> , 2020 , 9, e016115	6	28
264	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl 2020 , 15, e0240166		
263	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl 2020 , 15, e0240166		
262	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl 2020 , 15, e0240166		
261	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl 2020 , 15, e0240166		
260	Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e013229	6	8
259	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , 2019 , 188, 1033-1054	3.8	39
258	Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study. <i>BMJ, The</i> , 2019 , 364, k5420	5.9	26
257	Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. <i>Nature Communications</i> , 2019 , 10, 376	17.4	41
256	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2019 , 214, 113-124	4.9	9
255	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 525-537	4.9	33
254	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 1, 17-27	6.7	6
253	Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e011765	6	69
252	Development and validation of a clinical model for preconception and early pregnancy risk prediction of gestational diabetes mellitus in nulliparous women. <i>PLoS ONE</i> , 2019 , 14, e0215173	3.7	13

251	A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. <i>Human Molecular Genetics</i> , 2019 , 28, 2615-2633	5.6	14
250	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , 2019 , 51, 636-648	36.3	59
249	It's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause Mortality. <i>Journal of the American Heart Association</i> , 2019 , 8, e011378	6	11
248	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2019 , 140, e673-e691	16.7	169
247	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 735-743	4.9	1
246	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005562	5.8	61
245	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150mg doses. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 979-988.e10	4.9	9
244	Genetic Risk Scores for Maternal Lipid Levels and Their Association with Preterm Birth. <i>Lipids</i> , 2019 , 54, 641-650	1.6	
243	New insights into managing symptoms during statin therapy. <i>Progress in Cardiovascular Diseases</i> , 2019 , 62, 390-394	8.5	6
242	Lipid management beyond the guidelines. <i>Progress in Cardiovascular Diseases</i> , 2019 , 62, 384-389	8.5	6
241	Changes in physical and mental health are associated with cardiovascular disease incidence in postmenopausal women. <i>Age and Ageing</i> , 2019 , 48, 448-453	3	0
240	The next treatment paradigm in cardiovascular prevention?. <i>Lancet, The</i> , 2019 , 394, 2129-2131	40	
239	Can atherosclerosis be cured?. <i>Current Opinion in Lipidology</i> , 2019 , 30, 477-484	4.4	5
238	Development of a comprehensive health-risk prediction tool for postmenopausal women. <i>Menopause</i> , 2019 , 26, 1385-1394	2.5	3
237	ApoB in clinical care: Pro and Con. <i>Atherosclerosis</i> , 2019 , 282, 169-175	3.1	18
236	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1566-1579	27.4	205
235	A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. <i>American Journal of Human Genetics</i> , 2018 , 102, 375-400	11	59
234	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 119-127	6.4	11

233	Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 398-404	2.6	8
232	Optimizing Statins and Ezetimibe in Guideline-Focused Management. <i>Cardiology Clinics</i> , 2018 , 36, 221-223	5	2
231	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004249	5.8	13
230	Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
229	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction. <i>Pharmacotherapy</i> , 2018 , 38, 29-41	5.8	5
228	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. <i>JAMA Internal Medicine</i> , 2018 , 178, 1231-1240	11.5	36
227	First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018 , 13, e0201319	3.7	28
226	Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	3
225	Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018 , 41, 1328-1335	3.3	21
224	Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2018 , 12, 574-582	4.9	2
223	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. <i>JAMA Cardiology</i> , 2018 , 3, 739-748	16.2	48
222	Primary Prevention of Atherosclerotic Cardiovascular Disease 2018 , 433-458		
221	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. <i>JAMA Cardiology</i> , 2018 , 3, 1192-1199	16.2	19
220	Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. <i>Journal of the American Heart Association</i> , 2018 , 7, e007514	6	9
219	Maternal dyslipidemia and risk for preterm birth. <i>PLoS ONE</i> , 2018 , 13, e0209579	3.7	18
218	Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. <i>PLoS Medicine</i> , 2018 , 15, e1002670	11.6	89
217	Meta-analysis of LDL-C Lowering and Mortality-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1493-1494	27.4	
216	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , 2018 , 7, e009778	6	43

215	Long-Term Trends in Hypertension and Elevated Blood Pressure Among U.S. Adults, 1999 to 2016. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2089-2091	15.1	4
214	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018 , 7, e009251	6	5
213	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018 , 9, 1317-1334	3.6	18
212	Identifying Patients for Nonstatin Therapy. <i>Reviews in Cardiovascular Medicine</i> , 2018 , 19, S1-S8	3.9	5
211	Identifying Patients for Nonstatin Therapy. <i>Reviews in Cardiovascular Medicine</i> , 2018 , 19, 1-8	3.9	6
210	Can We Cure Atherosclerosis?. <i>Reviews in Cardiovascular Medicine</i> , 2018 , 19, 20-24	3.9	6
209	Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 250-259.e5	4.9	45
208	Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 471-482	15.1	133
207	Big Data Cohort Extraction to Facilitate Machine Learning to Improve Statin Treatment. <i>Western Journal of Nursing Research</i> , 2017 , 39, 42-62	2	6
206	The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study. <i>British Journal of Ophthalmology</i> , 2017 , 101, 926-932	5.5	15
205	Potential for Net Benefit Should Guide Preventive Therapy. <i>Circulation</i> , 2017 , 135, 630-632	16.7	2
204	Reply: Cost Effectiveness of Nonstatin-to-Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1996	15.1	
203	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2017 , 136, e1-e23	16.7	587
202	Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2017 , 106, 35-43	7	47
201	Chronic Use of Aspirin and Total White Matter Lesion Volume: Results from the Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, 2128-2136	2.8	5
200	Serum lipid changes following the onset of depressive symptoms in postmenopausal women. <i>Psychiatry Research</i> , 2017 , 247, 282-287	9.9	4
199	Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	20
198	Testing for type 2 diabetes in Indigenous Australians: guideline recommendations and current practice. <i>Medical Journal of Australia</i> , 2017 , 207, 206-210	4	2

197	Low Birth Weight and Risk of Later-Life Physical Disability in Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017 , 72, 543-547	6.4	1
196	Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1543-1554	15.1	48
195	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. <i>American Heart Journal</i> , 2017 , 193, 84-92	4.9	32
194	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 986-997	4.9	17
193	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017 , 377, 633-643	59.2	263
192	Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1201-1211	4.9	10
191	Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2017 , 121, 68-75	2.8	20
190	Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia. <i>Hypertension in Pregnancy</i> , 2017 , 36, 30-35	2	3
189	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , 2017 , 119, 40-46	3	98
188	More Dynamic Than You Think: Hidden Aspects of Decision-Making. <i>Administrative Sciences</i> , 2017 , 7, 23	2.5	9
187	Sleep duration, cognitive decline, and dementia risk in older women. <i>Alzheimeris and Dementia</i> , 2016 , 12, 21-33	1.2	99
186	Determining When to Add Nonstatin Therapy: A Quantitative Approach. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2412-2421	15.1	95
185	Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	59
184	Fine-mapping of lipid regions in global populations discovers ethnic-specific signals and refines previously identified lipid loci. <i>Human Molecular Genetics</i> , 2016 , 25, 5500-5512	5.6	22
183	Patterns of type 2 diabetes monitoring in rural towns: How does frequency of HbA1c and lipid testing compare with existing guidelines?. <i>Australian Journal of Rural Health</i> , 2016 , 24, 371-377	1.3	4
182	Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. <i>American Journal of Medicine</i> , 2016 , 129, 753.e13-22	2.4	14
181	Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2553-4	15.1	2
180	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 586-90	9.4	14

179	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 59-71	6.1	8
178	Embedding clinical interventions into observational studies. <i>Contemporary Clinical Trials</i> , 2016 , 46, 100-105		14
177	Biomimetic strategies for engineering composite tissues. <i>Current Opinion in Biotechnology</i> , 2016 , 40, 64-74	11.4	32
176	Correlates of Successful Aging in Racial and Ethnic Minority Women Age 80 Years and Older: Findings from the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016 , 71 Suppl 1, S87-99	6.4	8
175	Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons. <i>Nature Neuroscience</i> , 2016 , 19, 560-3	25.5	84
174	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 403-410	18.1	110
173	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016 , 16, 24	6.6	11
172	The Relationship of Cardiovascular Disease to Physical Functioning in Women Surviving to Age 80 and Above in the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016 , 71 Suppl 1, S42-53	6.4	11
171	The impact of birth weight on cardiovascular disease risk in the Women's Health Initiative. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 239-45	4.5	52
170	Optogenetic Activation of Septal Glutamatergic Neurons Drive Hippocampal Theta Rhythms. <i>Journal of Neuroscience</i> , 2016 , 36, 3016-23	6.6	76
169	Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia. <i>American Journal of Hypertension</i> , 2016 , 29, 17-24	2.3	11
168	Red Blood Cell Fatty Acids and Incident Diabetes Mellitus in the Women's Health Initiative Memory Study. <i>PLoS ONE</i> , 2016 , 11, e0147894	3.7	23
167	Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction. <i>Journal of the American Geriatrics Society</i> , 2016 , 64, 526-35	5.6	12
166	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 2144-2153	59.2	418
165	The future of lipid guidelines. <i>Current Opinion in Lipidology</i> , 2016 , 27, 585-591	4.4	2
164	Letter by Robinson Regarding Articles, "Bringing Back Targets to IMPROVE Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Cardiovascular Health and Incident Cardiovascular Disease and Cancer: The Women's Health Initiative. <i>American Journal of Preventive Medicine</i> , 2016 , 50, 236-40	16.7	
163		6.1	31
162	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2016 , 133, e615-53	16.7	24

161	Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. <i>American Journal of Cardiology</i> , 2016 , 118, 1805-1811	3	70
160	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016 , 37, 2981-2989	9.5	108
159	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia. <i>Progress in Cardiovascular Diseases</i> , 2016 , 59, 165-171	8.5	9
158	Statins and Primary Prevention of Cardiovascular Disease in Women: A Critical Appraisal of the Evidence. <i>American Journal of Lifestyle Medicine</i> , 2015 , 9, 114-129	1.9	2
157	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1489-99	59.2	1347
156	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3140-8	5.6	176
155	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1500-9	59.2	1081
154	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. <i>Progress in Cardiovascular Diseases</i> , 2015 , 58, 19-31	8.5	37
153	Statin use after acute myocardial infarction by patient complexity: are the rates right?. <i>Medical Care</i> , 2015 , 53, 324-31	3.1	8
152	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 2269-80	9.4	48
151	Progenitor Cells of the Mandibular Condylar Cartilage. <i>Current Molecular Biology Reports</i> , 2015 , 1, 110-114	114	7
150	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2015 , 170, 865-71	4.9	20
149	Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. <i>BMJ Open</i> , 2015 , 5, e007075	3	4
148	PCSK9 Inhibitors and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015 , 373, 774	59.2	27
147	Association between vitamin D status and age-related macular degeneration by genetic risk. <i>JAMA Ophthalmology</i> , 2015 , 133, 1171-9	3.9	32
146	Joint Associations of Diet, Lifestyle, and Genes with Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015 , 122, 2286-94	7.3	37
145	Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention. <i>Atherosclerosis</i> , 2015 , 243, 593-7	3.1	9
144	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015 , 385, 351-61	40	409

143	Statins for Primary Prevention in Adults Aged 75 Years or Older. <i>Annals of Internal Medicine</i> , 2015 , 163, 481	8	
142	Statins and diabetes risk: how real is it and what are the mechanisms?. <i>Current Opinion in Lipidology</i> , 2015 , 26, 228-35	4.4	38
141	The Relationship Between Serum 25-Hydroxyvitamin D Levels and Nuclear Cataract in the Carotenoid Age-Related Eye Study (CAREDS), an Ancillary Study of the Women's Health Initiative 2015 , 56, 4221-30		6
140	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. <i>European Heart Journal</i> , 2015 , 36, 2110-2118	9.5	44
139	Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women's Health Initiative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 309-16	5.8	15
138	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , 2015 , 169, 906-915.e13	4.9	251
137	Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. <i>American Journal of Hypertension</i> , 2015 , 28, 915-23	2.3	12
136	Diet drink consumption and the risk of cardiovascular events: a report from the Women's Health Initiative. <i>Journal of General Internal Medicine</i> , 2015 , 30, 462-8	4	26
135	Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. <i>American Journal of Human Genetics</i> , 2014 , 94, 223-32	11	233
134	Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. <i>American Journal of Human Genetics</i> , 2014 , 94, 233-45	11	170
133	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2889-934	15.1	2794
132	Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. <i>Human Molecular Genetics</i> , 2014 , 23, 1957-63	5.6	68
131	Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women. <i>Thyroid</i> , 2014 , 24, 1210-7	6.2	12
130	Starting primary prevention earlier with statins. <i>American Journal of Cardiology</i> , 2014 , 114, 1437-42	3	22
129	Birth weight and subsequent risk of cancer. <i>Cancer Epidemiology</i> , 2014 , 38, 538-43	2.8	38
128	Depressive Symptoms and Longitudinal Changes in Cognition: Women's Health Initiative Study of Cognitive Aging. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014 , 27, 94-102	3.8	19
127	Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. <i>American Journal of Epidemiology</i> , 2014 , 180, 346-58	3.8	117
126	Effect of long-chain n-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. <i>JAMA Internal Medicine</i> , 2014 , 174, 763-71	11.5	90

125	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014 , 176, 55-61	3.2	204
124	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 129, S49-73	16.7	2093
123	Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. <i>Cardiovascular Drugs and Therapy</i> , 2014 , 28, 281-9	3.9	78
122	2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial?. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 413	6	9
121	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i> , 2014 , 129, S1-45	16.7	2786
120	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2935-2959	15.1	1625
119	Loss-of-function mutations in APOC3, triglycerides, and coronary disease. <i>New England Journal of Medicine</i> , 2014 , 371, 22-31	59.2	721
118	Overview of 2013 American College of Cardiology/American Heart Association cholesterol guideline for reducing cardiovascular risk. <i>Clinical Practice (London, England)</i> , 2014 , 11, 273-275	3	
117	Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. <i>Annals of Internal Medicine</i> , 2014 , 160, 339-43	8	136
116	Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. <i>Clinical Cardiology</i> , 2014 , 37, 597-604	3.3	36
115	Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. <i>Circulation</i> , 2014 , 129, 754-63	16.7	79
114	Reply: Prevention and control of atherosclerosis: why are exercise and physical activity not getting the respect they deserve?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1761	15.1	
113	Comparison of lifestyle-based and traditional cardiovascular disease prediction in a multiethnic cohort of nonsmoking women. <i>Circulation</i> , 2014 , 130, 1466-73	16.7	16
112	Omega-3 fatty acid biomarkers and subsequent depressive symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 747-57	3.9	26
111	Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. <i>Clinical Cardiology</i> , 2014 , 37, 195-203	3.3	10
110	Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarction. <i>Medical Care</i> , 2014 , 52, 185-93	3.1	14
109	Geographic variation in statin use for complex acute myocardial infarction patients: evidence of effective care?. <i>Medical Care</i> , 2014 , 52 Suppl 3, S37-44	3.1	20
108	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1870-82	27.4	347

107	Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 157-62	5.8	67
106	Trajectories of positive aging: observations from the women's health initiative study. <i>International Psychogeriatrics</i> , 2014 , 26, 1351-62	3.4	9
105	Curing atherosclerosis should be the next major cardiovascular prevention goal. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2779-85	15.1	62
104	Can We Vaccinate Against Atherosclerosis and Prevent Cardiovascular Disease?. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 249-250	0.9	
103	Statins vs Early Hormone Therapy for the Primary Prevention of Cardiovascular Disease in Women. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 163-165	0.9	
102	Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1577-86	15.1	199
101	Coronary Heart Disease in Women & Men: Similar and Different. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 423-424	0.9	
100	Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations. <i>American Journal of Human Genetics</i> , 2013 , 92, 904-16	11	97
99	Self-reported snoring and risk of cardiovascular disease among postmenopausal women (from the Women's Health Initiative). <i>American Journal of Cardiology</i> , 2013 , 111, 540-6	3	39
98	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 292-303	4.9	13
97	The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). <i>Brain Research</i> , 2013 , 1514, 3-11	3.7	14
96	Lipids in Women 2013 , 965-974		
95	Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the Women's Health Initiative Magnetic Resonance Imaging studies. <i>Diabetes Care</i> , 2013 , 36, 90-7	14.6	88
94	Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory. <i>Journal of the American Medical Association: JAMA</i> , 2013 , 308, e226-31	8.6	121
93	Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. <i>JAMA Internal Medicine</i> , 2013 , 173, 1429-36	11.5	124
92	Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. <i>PLoS Genetics</i> , 2013 , 9, e1003379	6	94
91	Vitamin D intake and season modify the effects of the GC and CYP2R1 genes on 25-hydroxyvitamin D concentrations. <i>Journal of Nutrition</i> , 2013 , 143, 17-26	4.1	56
90	EB fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA. <i>Neurology</i> , 2013 , 81, 1484-91	6.5	31

89	Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women's Health Initiative Memory Study. <i>Journal of the American Heart Association</i> , 2013 , 2, e000369	6	80
88	Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Managed Care Pharmacy</i> , 2013 , 19, 139-49		79
87	Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 58-65	4.9	3
86	What is the role of advanced lipoprotein analysis in practice?. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2607-15	15.1	16
85	Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. <i>Journal of the American Geriatrics Society</i> , 2012 , 60, 2206-14	5.6	31
84	Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. <i>American Journal of Human Genetics</i> , 2012 , 91, 502-12	11	90
83	Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. <i>American Journal of Cardiology</i> , 2012 , 110, 1468-76	3	86
82	Correcting the effects of -20 °C storage and aliquot size on erythrocyte fatty acid content in the Women's Health Initiative. <i>Lipids</i> , 2012 , 47, 835-46	1.6	51
81	Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. <i>Circulation</i> , 2012 , 125, 1748-56, S1-11	16.7	168
80	Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. <i>Genome Medicine</i> , 2012 , 4, 57	14.4	7
79	Evaluation of the metabochip genotyping array in African Americans and implications for fine mapping of GWAS-identified loci: the PAGE study. <i>PLoS ONE</i> , 2012 , 7, e35651	3.7	59
78	Identification and Treatment of Women with Familial Hypercholesterolemia. <i>Current Cardiovascular Risk Reports</i> , 2012 , 6, 196-204	0.9	
77	Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 1108-16	6.4	35
76	Racial and ethnic differences in incident hospitalized heart failure in postmenopausal women: the Women's Health Initiative. <i>Circulation</i> , 2012 , 126, 688-96	16.7	34
75	Clinical utility of lipoprotein-associated phospholipase A _{II} for cardiovascular disease prediction in a multiethnic cohort of women. <i>Clinical Chemistry</i> , 2012 , 58, 1352-63	5.5	22
74	In search of self-awareness: results of the National Lipid Association 2010 Lipid Pulse membership survey. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 12-7	4.9	0
73	Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, 133-140	4.9	181
72	Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S18-29	4.9	90

71	Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S46-51	4.9	24
70	Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S1-8	4.9	329
69	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). <i>Journal of Clinical Lipidology</i> , 2011 , 5, 474-82	4.9	17
68	Is there a future for CETP-inhibitor therapy?. <i>Clinical Investigation</i> , 2011 , 1, 367-370		
67	Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's Health Initiative (WHI). <i>American Journal of Clinical Nutrition</i> , 2011 , 94, 1471-87		46
66	Fish intake and the risk of incident heart failure: the Women's Health Initiative. <i>Circulation: Heart Failure</i> , 2011 , 4, 404-13	7.6	56
65	Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 131-45	2.5	13
64	Lack of association between 25(OH)D levels and incident type 2 diabetes in older women. <i>Diabetes Care</i> , 2011 , 34, 628-34	14.6	69
63	Response to Letter Regarding Article, "Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women's Health Initiative". <i>Circulation</i> , 2010 , 121, e408	16.7	1
62	Evaluation of the American Heart Association cardiovascular disease prevention guideline for women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 128-34	5.8	25
61	Fatty acid consumption and risk of fracture in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2010 , 92, 1452-60	7	73
60	Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2010 , 91, 894-9	7	84
59	Dalcetrapib: a review of Phase II data. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 795-805	5.9	31
58	Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. <i>American Journal of Clinical Nutrition</i> , 2010 , 91, 860-74	7	37
57	Clopidogrel and neuraxial block: the role of the PFA II and P2Y12 assays. <i>Regional Anesthesia and Pain Medicine</i> , 2010 , 35, 115	3.4	9
56	A uniform approach to modeling risk factor relationships for ischemic lesion prevalence and extent: the Women's Health Initiative Magnetic Resonance Imaging study. <i>Neuroepidemiology</i> , 2010 , 34, 55-62	5.4	4
55	Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. <i>European Heart Journal</i> , 2010 , 31, 480-8	9.5	96
54	Omega-3 fatty acids and cognitive function in women. <i>Women's Health</i> , 2010 , 6, 119-34	3	34

53	Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2080-91	15.1	92
52	Another treatment gap: restarting secondary prevention medications: the Women's Health Initiative. <i>Journal of Clinical Lipidology</i> , 2010 , 4, 36-45	4.9	10
51	Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. <i>Journal of Clinical Lipidology</i> , 2010 , 4, 483-90	4.9	32
50	How Low to Go for Primary Prevention?. <i>Current Cardiovascular Risk Reports</i> , 2010 , 4, 245-247	0.9	
49	Management of the patient with statin intolerance. <i>Current Atherosclerosis Reports</i> , 2010 , 12, 48-57	6	32
48	Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 203-12	2.3	41
47	The cross-sectional relationship between body mass index, waist-hip ratio, and cognitive performance in postmenopausal women enrolled in the Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 1427-32	5.6	31
46	Alcohol consumption, hypertension, and total mortality among women. <i>American Journal of Hypertension</i> , 2009 , 22, 1212-8	2.3	21
45	Optimism, cynical hostility, and incident coronary heart disease and mortality in the Women's Health Initiative. <i>Circulation</i> , 2009 , 120, 656-62	16.7	307
44	Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. <i>BMC Cardiovascular Disorders</i> , 2009 , 9, 46	2.3	23
43	Attitudes about health and health-related behaviors in patients with cardiovascular disease or at elevated risk for cardiovascular disease. <i>Preventive Cardiology</i> , 2009 , 12, 136-43		9
42	Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). <i>American Journal of Cardiology</i> , 2009 , 103, 1694-702	3	55
41	Family history of myocardial infarction predicts incident coronary heart disease in postmenopausal women with diabetes: the Women's Health Initiative Observational Study. <i>Diabetes/Metabolism Research and Reviews</i> , 2009 , 25, 725-32	7.5	5
40	Is a statin as part of a polypill the answer?. <i>Current Atherosclerosis Reports</i> , 2009 , 11, 15-22	6	3
39	Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 316-22	15.1	280
38	Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. <i>Drugs and Aging</i> , 2009 , 26, 917-31	4.7	12
37	Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. <i>Vascular Health and Risk Management</i> , 2009 , 5, 31-43	4.4	8
36	A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , 2008 , 56, 1449-58	5.6	42

35	Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. <i>American Journal of Cardiology</i> , 2008 , 101, 1009-15 ³		29
34	Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials). <i>American Journal of Cardiology</i> , 2008 , 102, 693-9	3	41
33	Association between different measures of blood pressure and coronary artery calcium in postmenopausal women. <i>Hypertension</i> , 2008 , 52, 833-40	8.5	8
32	Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. <i>PPAR Research</i> , 2008 , 2008, 891425	4.3	16
31	Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. <i>Clinical Trials</i> , 2008 , 5, 240-7	2.2	194
30	Affecting behavior change in individuals with diabetes: findings from the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD). <i>The Diabetes Educator</i> , 2008 , 34, 1025-36	2.5	29
29	Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 1666-71	9.4	46
28	LDL reduction: how low should we go and is it safe?. <i>Current Cardiology Reports</i> , 2008 , 10, 481-7	4.2	3
27	Simvastatin: present and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 2159-27	4	17
26	Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). <i>Academic Radiology</i> , 2007 , 14, 603-12	4.3	35
25	Safety of aggressive lipid management. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1753-62	15.1	123
24	Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. <i>Current Atherosclerosis Reports</i> , 2007 , 9, 64-71	6	12
23	Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. <i>PLOS Clinical Trials</i> , 2007 , 2, e28		29
22	Is it time for a cardiovascular primary prevention trial in the elderly?. <i>Stroke</i> , 2007 , 38, 441-50	6.7	48
21	Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. <i>Aging Health</i> , 2007 , 3, 691-705		23
20	Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. <i>Future Lipidology</i> , 2007 , 2, 285-301		6
19	Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. <i>American Journal of Cardiology</i> , 2006 , 98, 39i-49i	3	140
18	Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment. <i>American Journal of Cardiology</i> , 2006 , 97, 1667-9	3	5

17	How low to target LDL?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 414-5		1
16	Lipid-lowering effects of statins: a comparative review. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1701-14		37
15	Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial. <i>PLOS Clinical Trials</i> , 2006 , 1, e26		2
14	Elderly women diagnosed with nonspecific chest pain may be at increased cardiovascular risk. <i>Journal of Women's Health</i> , 2006 , 15, 1151-60	3	17
13	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <i>Expert Review of Cardiovascular Therapy</i> , 2006 , 4, 461-76	2.5	37
12	Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. <i>American Heart Journal</i> , 2006 , 152, 170-6	4.9	53
11	Managing cholesterol in the elderly. <i>Aging Health</i> , 2006 , 2, 623-638		
10	Management of Elevated Low-Density Lipoprotein Cholesterol. <i>Fundamental and Clinical Cardiology</i> , 2006 , 255-294		
9	Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1855-62	15.1	331
8	A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. <i>American Journal of Cardiology</i> , 2005 , 95, 373-8	3	38
7	Sharon Monteith, <i>Advancing Sisterhood?: Interracial Friendships in Contemporary Southern Fiction</i> (Athens: the University of Georgia Press, 2000, \$40). Pp. 241. ISBN 0 8203 2249 0.. <i>Journal of American Studies</i> , 2002 , 36, 513-570	0.1	
6	Comparison of effectiveness and safety of simvastatin in patients \geq 75 years of age with coronary, cerebral, or peripheral arterial disease. <i>American Journal of Cardiology</i> , 2002 , 90, 994-5	3	1
5	Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. <i>Menopause</i> , 2001 , 8, 17-26	2.5	131
4	A Comparison of NCEP and Absolute Risk Stratification Methods for Lipid-Lowering Therapy in Middle-Aged Adults: The ARIC Study. The ARIC Investigators. <i>Preventive Cardiology</i> , 2001 , 4, 148-157		2
3	Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. <i>Journal of Nutrition</i> , 2001 , 131, 2280-7	4.1	61
2	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol <i>American Journal of Cardiology</i> , 2000 , 85, 305-8	3	35
1	Noninvasive pulse wave analysis for the early detection of vascular disease. <i>Hypertension</i> , 1995 , 26, 503-8.5		314